Early evidence suggests that plasma p-tau181 becomes abnormal approximately 6 years after an individual reaches abnormal levels of amyloid-β,30 in line with established biomarker models from autosomal-dominant31 and sporadic32 Alzheimer’s disease in which amyloid-β abnormality precedes tau abnormality. The gene discussed is MAPT; the disease is Alzheimer disease.